BC Week In Review | Mar 9, 2015
Clinical News

ISIS-PKKRx: Phase I data

A placebo-controlled, dose-escalation, Canadian Phase I trial in 48 healthy volunteers showed that single doses of 50-400 mg subcutaneous ISIS-PKKRx and once-weekly doses of 100-400 mg subcutaneous ISIS-PKKRx for 3 weeks were generally well tolerated....
BC Innovations | Sep 25, 2008
Targets & Mechanisms

New Roles for Old Factor

Researchers at the University Medical Center Utrecht and Crossbeta Biosciences B.V. have linked high levels of activated Factor XII with amyloidosis, a metabolic disease that is characterized by misfolded protein aggregates. 1 The company plans...
Items per page:
1 - 2 of 2